Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares were down 2.5% on Wednesday . The company traded as low as $20.72 and last traded at $21.05. Approximately 431,408 shares changed hands during trading, a decline of 61% from the average daily volume of 1,095,667 shares. The stock had previously closed at $21.60.
Analyst Ratings Changes
A number of research firms recently commented on CAPR. Maxim Group increased their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. Finally, Oppenheimer reissued an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $22.60.
Get Our Latest Stock Analysis on Capricor Therapeutics
Capricor Therapeutics Stock Down 5.0 %
The stock has a market cap of $655.89 million, a price-to-earnings ratio of -23.34 and a beta of 4.01. The company's 50-day moving average is $8.11 and its 200-day moving average is $6.26.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. On average, research analysts forecast that Capricor Therapeutics Inc will post -1.13 earnings per share for the current year.
Insider Buying and Selling
In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company's stock in a transaction on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.00% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Capricor Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in CAPR. Vanguard Group Inc. increased its holdings in Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock worth $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter valued at approximately $426,000. Bank of New York Mellon Corp boosted its position in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after acquiring an additional 9,040 shares during the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Institutional investors and hedge funds own 21.68% of the company's stock.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
